Epigenomics, Qiagen Ink Colorectal Cancer Option Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Epigenomcs and Qiagen today announced an option agreement allowing Qiagen to develop a colorectal cancer blood test based on Epigenomics' mSept9 biomarker and certain DNA methylation analysis technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.